Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 15/20 | 0.56 |
| ▸ | CDK8 | P49336 | 15/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 5/20 | 0.43 |
| ▸ | SELE | P16581 | 5/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051642 | 0.86 | CCNC (0.63) | CCNCCDK8CCNT1CDK9ICAM1 | |
| SCHEMBL7054268 | 0.78 | CCNC (0.75) | CCNCCDK8CCNT1CDK9ICAM1 | |
| SCHEMBL7055327 | 0.76 | CCNC (0.64) | CCNCCDK8CCNT1CDK9ICAM1 | |
| SCHEMBL5550146 | 0.74 | CSNK2A2 (0.43) | CCNCCDK8ICAM1SELEVCAM1 | |
| SCHEMBL7057140 | 0.72 | CDK8 (1.00) | CCNCCDK8CCNT1CDK9ICAM1 | |
| SCHEMBL7056641 | 0.69 | CCNC (0.62) | CCNCCDK8CCNT1CDK9ICAM1 | |
| SCHEMBL22859936 | 0.69 | GSK3B (0.46) | CCNCCDK8ICAM1SELEVCAM1 | |
| SCHEMBL25948367 | 0.68 | CCNC (0.58) | CCNCCDK8CCNT1CDK9ICAM1 | |
| SCHEMBL7055038 | 0.67 | CCNC (0.67) | CCNCCDK8CCNT1CDK9ICAM1 | |
| SCHEMBL30627005 | 0.66 | MAPT (0.54) | CCNCCDK8KMT2AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6579882-B2 | Thieno(2,3-d)pyrimidine derivatives | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | CCNC 1780/4885CDK8 2986/4885CCNT1 1245/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | CCNC 1780/4885CDK8 2986/4885CCNT1 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.